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MaBACKGROUND Severe tricuspid regurgitation is associated with poor prognosis; however, there are limited Class I
indications for intervention, and high–surgical risk patients may go untreated. We report the ﬁrst-in-human successful
transcatheter tricuspid valve repair for severe tricuspid regurgitation.
OBJECTIVES The objective of this study was to show the feasibility of a transcatheter tricuspid annular repair.
METHODS Compassionate-use approval for the procedure was obtained from the regulatory organization in Germany.
To perform the transcatheter bicuspidization of the tricuspid valve, the Mitralign system was used to place pledgeted
sutures by means of a trans-jugular venous approach. Insulated radiofrequency wires were positioned 2 to 5 mm from
the base of the posterior leaﬂet, 2.6 cm apart. The sutures were drawn together and locked, plicating the posterior annulus.
RESULTS Reconstruction of the 3-dimensional transesophageal echocardiographic dataset at baseline revealed a
tricuspid valve annular area of 14.1 cm2, and effective regurgitant oriﬁce area was 1.35 cm2. There was a signiﬁcant
reduction in annular area (57%) and effective regurgitant oriﬁce area (53%) measured with 3-dimensional transeso-
phageal echocardiography, at 6.05 cm2 and 0.63 cm2, respectively. Hemodynamic parameters also improved with a
reduction in right atrial pressure from 22 mm Hg at baseline, to 9 mm Hg and an increase in left ventricular stroke volume
from 42 ml at baseline to 72 ml.
CONCLUSIONS Transcatheter tricuspid valve repair could become an effective treatment for high–surgical risk patients
who are non-responsive to optimal medical therapy. (J Am Coll Cardiol 2015;65:1190–5) © 2015 by the American College
of Cardiology Foundation.A growing number of studies suggest that se-vere tricuspid regurgitation (TR) is associ-ated with poor prognosis (1–7). Class I
indication for TR repair is currently limited to pa-
tients with concomitant mitral valve disease
requiring surgery (Level of Evidence: B) (8). Multiple
surgical repair procedures have been proposed,
including the Kay bicuspidization procedure (9), in
which the annulus is plicated along its muscular
part adjacent to the posterior leaﬂet. This repair
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LV = left ventricular
TEE = transesophageal
echocardiogram
TR = tricuspid regurgitation
TTVR = transcatheter
tricuspid valve repair
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1191III/IV chronic kidney disease (creatinine ¼ 1.85 ml/dl,
glomerular ﬁltration rate ¼ 27 ml/min), and chronic
atrial ﬁbrillation. Echocardiography showed pre-
served left ventricular (LV) size and function (ejection
fraction, 55%) with reduced forward stroke volume
(42 ml); mild to moderate mitral and aortic regurgi-
tation; severe dilation of the right atrium and
ventricle with slightly impaired right ventricular
function; and severe TR with tethered, non-thickened
leaﬂets. Right heart catheterization revealed a right
atrial pressure of 22 mm Hg and pulmonary artery
systolic pressure of 40 mm Hg. The echocardio-FIGURE 1 Retrograde Approach to the Tricuspid Annulus
Accurate placement of the guide catheter is essential for safe placement of the sutured
pledgets. (A) Articulated catheter (dashed yellow line) approaching the tricuspid annulus
close the right coronary artery (RCA) (red arrow). (B) Repositioned guide catheter pointed
away from the RCA.
SEE PAGE 1196graphic and hemodynamic ﬁndings are consistent
with “isolated tricuspid regurgitation” (7). The pa-
tient’s Log EuroSCORE (European System for Cardiac
Operative Risk Evaluation) was 28%, and surgical
intervention was deemed too high-risk; she agreed
to undergo a transcatheter bicuspidization of her
tricuspid valve. Because there are no currently
accepted indications for intervention in the absence
of concomitant mitral valve disease, we approached
the regulatory organization in Germany (Bundesin-
stitut für Arzneimittel und Medizinprodukte), which
approved compassionate use of the Mitralign system
(Mitralign Inc., Tewksbury, Massachusetts) to plicate
the tricuspid annulus.
PROCEDURE. With the patient under general anes-
thesia, 2- and 3-dimensional (2D and 3D) trans-
esophageal echocardiography (TEE) was performed at
baseline, during and after the procedure. To perform
the transcatheter bicuspidization of the tricuspid
valve, we used the Mitralign system to place pledg-
eted sutures by means of a trans-jugular venous
approach. Over a standard angiographic wire, we
introduced an articulating 8-F wire delivery catheter
in a retrograde fashion across the tricuspid. The
retrograde approach allows for better control and
accuracy of placement of the wires into the annulus
while TEE guidance is used. An 8-F deﬂectable cath-
eter was advanced across the tricuspid valve and
positioned into the right ventricle by means of echo-
cardiographic guidance. Once introduced into the
right ventricle, the catheter was articulated under the
annulus to either the postero-anterior commissure or
the septo-posterior commissure. Once the anatomic
site was conﬁrmed on ﬂuoroscopy and TEE, an insu-
lated radiofrequency wire was advanced and posi-
tioned 2 to 5 mm from the base of the leaﬂet and
within the annulus, directed toward the right atrium
to avoid right coronary artery perforation (Figure 1).
Once the wire was through the annulus, a pledgetdelivery catheter was advanced over the wire
from the right atrium across the annulus to
the right ventricle. The wire was removed,
and half the pledget was delivered and
cinched in the sub-annular region of the
ventricle. On withdrawal of the pledget de-
livery catheter from the ventricle, the
remaining pledget was extruded and cinched
on the atrial surface of the tricuspid annulus.
The end result was a suture supported on
both the ventricular and atrial sides of the
annulus with folded pledgets (Figure 2). The
steps were then repeated on the opposite
anatomic site of the posterior commissure. A dedi-
cated plication lock device was used to bring the 2
pledgeted sutures together, plicating the annulus
and effectively bicuspidizing the tricuspid valve
(Figure 3).
RESULTS
Reconstruction of the 3D TEE dataset at baseline re-
vealed a tricuspid valve annular area of 14.1 cm2 and
effective regurgitant oriﬁce area (EROA) of 1.35 cm2
(Figure 4). There was a signiﬁcant reduction in annular
area (57%) and EROA (53%) measured with 3D TEE, at
6.05 cm2 and 0.63 cm2, respectively. Hemodynamic
parameters also improved, with a reduction in right
atrial pressure from 22 mm Hg at baseline to 9 mm Hg
and an increase in LV stroke volume from 42 ml
at baseline to 72 ml. The patient tolerated the proce-
dure well, was extubated the same day, and was dis-
charged 5 days after the procedure. Since discharge,
FIGURE 2 Delivery of a Sutured Pledget
A dedicated plication lock device was used to bring the 2 pledgeted sutures together,
plicating the annulus and effectively bicuspidizing the tricuspid valve. (A) Illustration of
the sutures placed in the postero-anterior commissure and the septo-posterior commissure
(yellow arrows). (B) Illustration of the 2 sutures after plication. Patient’s 3-dimensional
transesophageal echocardiographic images are shown before plication (C) and after
plication (D). Ant ¼ anterior leaﬂet; Post ¼ posterior leaﬂet; Sept ¼ septal leaﬂet.
FIGURE 3 Plication of the Tricuspid Annulus
An insulated radiofrequency wire was advanced and a sutured pledget wa
3-dimensional transesophageal echocardiographic image of the actual pl
(yellow arrow). RA ¼ right atrium; RV ¼ right ventricle.
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1192the patient has continued to require her usual
aggressive medical management; however, she sub-
jectively feels better, her edema has lessened, and her
renal function has signiﬁcantly improved (creatinine
¼ 1.0 ml/dl, glomerular ﬁltration rate ¼ 55 ml/min).
DISCUSSION
Functional or secondary TR is the most common eti-
ology of severe TR in the Western world (12). Interest
in the tricuspid valve has increased in recent years
(13–15) with the recognition of the impact of second-
ary tricuspid regurgitation on outcomes (1,2,5,7,16,17)
and the beneﬁts of tricuspid repair (6,18). TR is an
independent predictor of long-term mortality (2,7).
The prevalence of secondary TR with mitral valve
disease is >30% (13,14), with some studies suggesting
that more than 1.6 million patients in the United
States may have this disease (19).
Outcomes related to isolated tricuspid regurgitation—
similar to our case—were recently studied by Topilsky
et al. (7). These authors deﬁned isolated TR as requiring
the following: 1) TR holosystolic and functional; 2) no
probable pulmonary hypertension (<50 mm Hg); 3) no
overt TR cause (no intrinsic tricuspid disease, LV
ejection fraction $50%, no pacemaker/deﬁbrillator
wire across the tricuspid, no other valve disease
more than mild, no disease that may cause TR, no
congenital or pericardial heart disease); and 4) nos deployed with the use of the wire as a guide rail. (A) Illustration with
edgeted suture. (B) Fluoroscopic appearance of the pledgeted suture
FIGURE 4 3-Dimensional Transesophageal Echocardiographic Annular and Regurgitant Oriﬁce Changes
Multi-planar 3-dimensional (3D) transesophageal echocardiographic reconstruction was used to assess the changes after annuloplasty. (A) 3D reconstruction of the
annulus and effective regurgitant oriﬁce area (EROA) at baseline with the associated 3D volume (B). (C) 3D reconstruction of the annulus and EROA after transcatheter
tricuspid annuloplasty with the associated 3D volume (D).
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1193previous valve surgery. Patients with isolated,
severe TR had a signiﬁcantly reduced 10-year sur-
vival compared with patients with less signi-
ﬁcant disease. In this study, both the qualitative
multi-window, multi-parameter method (adjusted
hazard ratio [HR]: 1.78; 95% conﬁdence interval
[CI]: 1.10 to 2.82; p ¼ 0.02) and proximal isovelocity
surface area quantitative EROA $40 mm2 (adjusted
HR: 2.67; 95% CI: 1.66 to 4.23; p < 0.0001)
independently predicted higher mortality rates.
Adverse outcomes with EROA $40 mm2 were seen,
independent of all other characteristics, such as right
ventricular size or function, comorbidity, or pulmo-
nary pressure (p < 0.0001 for all).
Currently, TR is treated primarily with optimal
medical therapy or surgery (20). In patients who have
development of severe TR late after left heart valve
surgery, operativemortality rate may be as high as 10%
to 20% (13,21–23). In patients who have failed initial
surgical repair of the tricuspid valve, transcatheterplacement of balloon-expandable valves (valve-in-
ring) have been successfully performed (24). In addi-
tion, indirect transcatheter procedures have been
reported for the treatment of severe, symptomatic
secondary tricuspid regurgitation. These techniques
focus on reducing the regurgitant ﬂow into the vena
cava by the implantation of transcatheter valves in
these large vessels (25,26). This solution, however,
fails to treat the primary disease process of the
tricuspid valve, although Laule et al. (26) reported
remodeling of the right heart.
This ﬁrst-in-human report of a direct TTVR
approach shows the feasibility and safety of this
procedure as well as a signiﬁcant reduction in annular
area and EROA, resulting in a marked reduction in
TR (Central Illustration). As a consequence, right atrial
pressure and LV stroke volume showed marked
improvement. Anatomic imaging with the use of
2D and 3D TEE was integral to the success of the
procedure. The new comprehensive TEE guideline,
CENTRAL ILLUSTRATION Transcatheter Tricuspid Valve Repair: Multi-Planar 3-Dimensional
Transesophageal Echocardiographic Reconstruction
Baseline images of the native tricuspid annulus are shown. (A) Image of the native tricuspid annulus before repair; (B) image of 3-dimensional reconstruction of
the annulus and effective regurgitant oriﬁce area (EROA); (C) associated 3-dimensional volume. (D to F) Corresponding post–transcatheter tricuspid valve repair images of
the tricuspid annulus. Asterisks in E and F show the position of the pledgeted sutures. A ¼ anterior tricuspid valve leaﬂet; S ¼ septal leaﬂet; P ¼ posterior leaﬂet.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: The
Mitralign device, designed to plicate the annulus of
the mitral valve, may be applicable to the tricuspid
valve as well.
TRANSLATIONAL OUTLOOK: Additional experi-
ence with this percutaneous, transesophageal, echo-
cardiographically guided procedure to reduce the
diameter of the valve annulus and lessen tricuspid
regurgitation is needed to better deﬁne its role in
patients with severe primary or secondary tricuspid
regurgitation. Assessment of the effect of the pro-
cedure on symptoms, right heart remodeling, and
clinical outcomes requires clinical trials involving
additional patients.
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1194published by the American Society of Echocardiog-
raphy (27), describes advanced imaging views for the
tricuspid valve. The use of 3D technology, whether
simultaneous multiplane imaging or full-volume ac-
quisitions (28), allows for the precise placement of
catheters and wires. Both 2D and 3D TEE were
essential adjuncts to ﬂuoroscopic imaging for precise
positioning of the pledgeted sutures in the annulus,
as well as for avoidance of complications such as
coronary or chamber perforation. Thus, TEE imaging
was integral to the success of the current procedure.
STUDY LIMITATIONS. This is a single case report
showing feasibility and reduction in annular di-
mensions for isolated TR. The durability and long-
term effect of TTVR, as well as the efﬁcacy for other
etiologies of TR, should be studied in larger trials.
CONCLUSIONS
This case provides a proof of principle that a direct
TTVR for severe TR could become an effective
treatment for high–surgical risk patients who are
non-responsive to optimal medical therapy. Larger
numbers of patients are needed to assess the feasi-
bility and efﬁcacy of this treatment.REPRINT REQUESTS AND CORRESPONDENCE: Dr.
Rebecca T. Hahn, Columbia University Medical
Center, New York-Presbyterian Hospital, 177 Fort
Washington Avenue, New York, New York 10032.
E-mail: rth2@columbia.edu.
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